Cutaneous Lupus Erythematosus (CLE)

Immunology
3
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 2 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

GS
Gilead SciencesFOSTER CITY, CA
1 program
1
EdecesertibPhase 2Small Molecule1 trial
Active Trials
NCT05629208Terminated20Est. Jan 2026
InnoCare
InnoCareChina - Beijing
1 program
1
ICP-488 TabletsPhase 21 trial
Active Trials
NCT07440537Not Yet Recruiting105Est. Dec 2027
Ventus Therapeutics
1 program
1
VENT-03Phase 21 trial
Active Trials
NCT07260877Recruiting24Est. Sep 2026

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
2027
InnoCareICP-488 Tablets
Ventus TherapeuticsVENT-03
Gilead SciencesEdecesertib

Clinical Trials (3)

Total enrollment: 149 patients across 3 trials

NCT07440537InnoCareICP-488 Tablets

Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study

Start: Mar 2026Est. completion: Dec 2027105 patients
Phase 2Not Yet Recruiting

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus

Start: Dec 2025Est. completion: Sep 202624 patients
Phase 2Recruiting

Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)

Start: Apr 2023Est. completion: Jan 202620 patients
Phase 2Terminated

Related Jobs in Immunology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 149 patients
3 companies competing in this space